Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy

Chemokines can induce chemotactic cell migration by interacting with G protein-coupled receptors to play a significant regulatory role in the development of cancer. CXC chemokine-12 (CXCL12) can specifically bind to CXC chemokine receptor 4 (CXCR4) and is closely associated with the progression of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ruogang, Liu, Jianhao, Li, Zhaohuan, Zhang, Wenhui, Wang, Feng, Zhang, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332179/
https://www.ncbi.nlm.nih.gov/pubmed/35893797
http://dx.doi.org/10.3390/pharmaceutics14081541
_version_ 1784758583062167552
author Zhao, Ruogang
Liu, Jianhao
Li, Zhaohuan
Zhang, Wenhui
Wang, Feng
Zhang, Bo
author_facet Zhao, Ruogang
Liu, Jianhao
Li, Zhaohuan
Zhang, Wenhui
Wang, Feng
Zhang, Bo
author_sort Zhao, Ruogang
collection PubMed
description Chemokines can induce chemotactic cell migration by interacting with G protein-coupled receptors to play a significant regulatory role in the development of cancer. CXC chemokine-12 (CXCL12) can specifically bind to CXC chemokine receptor 4 (CXCR4) and is closely associated with the progression of cancer via multiple signaling pathways. Over recent years, many CXCR4 antagonists have been tested in clinical trials; however, Plerixafor (AMD3100) is the only drug that has been approved for marketing thus far. In this review, we first summarize the mechanisms that mediate the physiological effects of the CXCL12/CXCR4 axis. Then, we describe the use of CXCL12/CXCR4 antagonists. Finally, we discuss the use of nano-based drug delivery systems that exert action on the CXCL12/CXCR4 biological axis.
format Online
Article
Text
id pubmed-9332179
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93321792022-07-29 Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy Zhao, Ruogang Liu, Jianhao Li, Zhaohuan Zhang, Wenhui Wang, Feng Zhang, Bo Pharmaceutics Review Chemokines can induce chemotactic cell migration by interacting with G protein-coupled receptors to play a significant regulatory role in the development of cancer. CXC chemokine-12 (CXCL12) can specifically bind to CXC chemokine receptor 4 (CXCR4) and is closely associated with the progression of cancer via multiple signaling pathways. Over recent years, many CXCR4 antagonists have been tested in clinical trials; however, Plerixafor (AMD3100) is the only drug that has been approved for marketing thus far. In this review, we first summarize the mechanisms that mediate the physiological effects of the CXCL12/CXCR4 axis. Then, we describe the use of CXCL12/CXCR4 antagonists. Finally, we discuss the use of nano-based drug delivery systems that exert action on the CXCL12/CXCR4 biological axis. MDPI 2022-07-25 /pmc/articles/PMC9332179/ /pubmed/35893797 http://dx.doi.org/10.3390/pharmaceutics14081541 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zhao, Ruogang
Liu, Jianhao
Li, Zhaohuan
Zhang, Wenhui
Wang, Feng
Zhang, Bo
Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy
title Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy
title_full Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy
title_fullStr Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy
title_full_unstemmed Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy
title_short Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy
title_sort recent advances in cxcl12/cxcr4 antagonists and nano-based drug delivery systems for cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332179/
https://www.ncbi.nlm.nih.gov/pubmed/35893797
http://dx.doi.org/10.3390/pharmaceutics14081541
work_keys_str_mv AT zhaoruogang recentadvancesincxcl12cxcr4antagonistsandnanobaseddrugdeliverysystemsforcancertherapy
AT liujianhao recentadvancesincxcl12cxcr4antagonistsandnanobaseddrugdeliverysystemsforcancertherapy
AT lizhaohuan recentadvancesincxcl12cxcr4antagonistsandnanobaseddrugdeliverysystemsforcancertherapy
AT zhangwenhui recentadvancesincxcl12cxcr4antagonistsandnanobaseddrugdeliverysystemsforcancertherapy
AT wangfeng recentadvancesincxcl12cxcr4antagonistsandnanobaseddrugdeliverysystemsforcancertherapy
AT zhangbo recentadvancesincxcl12cxcr4antagonistsandnanobaseddrugdeliverysystemsforcancertherapy

Ejemplares similares